Joseph Todisco - 18 Dec 2025 Form 4 Insider Report for CorMedix Inc. (CRMD)

Role
Chief Executive Officer, Director
Signature
/s/ Joseph Todisco
Issuer symbol
CRMD
Transactions as of
18 Dec 2025
Net transactions value
-$227,100
Form type
4
Filing time
19 Dec 2025, 21:30:16 UTC
Previous filing
16 Oct 2025
Next filing
20 Jan 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Todisco Joseph Chief Executive Officer, Director C/O CORMEDIX INC., 300 CONNELL DRIVE, SUITE 4200, BERKELEY HEIGHTS /s/ Joseph Todisco 19 Dec 2025 0001774807

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CRMD Common Stock Options Exercise $132,900 +30,000 +5.9% $4.43 539,496 18 Dec 2025 Direct
transaction CRMD Common Stock Sale $360,000 -30,000 -5.6% $12.00 509,496 18 Dec 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CRMD Stock Option (Right to Buy Common Stock) Options Exercise $0 -30,000 -7.5% $0.000000 370,000 18 Dec 2025 Common Stock 30,000 $4.43 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 This transaction was executed in multiple trades at prices ranging from $12.00 to $12.02, inclusive. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
F2 These options were granted on 01/14/2023. These options vest 1/4 on the date of grant, and, subject to continued employment, 1/4 on the first anniversary of the date of grant, 1/4 on the second anniversary of the date of grant and 1/4 on the third anniversary of the date of grant.